← SynDRA
LIXIVAPTAN
SynDRA canonical compound SYN0002390 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
| Primary target(s) | AVPR2 |
| Mechanism of action | vasopressin receptor antagonist |
All known targets
Mechanisms of action (all sources)
- AVPR2 ANTAGONIST
- Vasopressin V2 receptor antagonist
- AVPR2 INVERSE AGONIST
- vasopressin receptor antagonist
- HDC INHIBITOR
Cross-references
Synonyms
- VPA-985
- CRTX-080
- CRTX080
- VPA985
- WAY-VPA-985
- Lixar
- VPA 985
- WAY-VPA 985
- UNII-8F5X4B082E
- CHEMBL49429
- 8F5X4B082E
- N-[3-chloro-4-(6,11-dihydropyrrolo[2,1-c][1,4]benzodiazepine-5-carbonyl)phenyl]-5-fluoro-2-methylbenzamide
- Lixivaptan [USAN:INN]
- Lixivaptan (USAN/INN)
- Lixivaptan (VPA-985)
- AC1L59LM
- GTPL2238
- SCHEMBL1649340
- DTXSID00168472
- PPHTXRNHTVLQED-UHFFFAOYSA-N
- ZINC600399
- EX-A1129
- BCP09167
- BDBM50065115
- AKOS022181388
- AN-1842
- CS-7512
- API0009250
- NCGC00485402-01
- BF-Derm1
- CRTX 080
- lixivaptanum
- RefChem:800001
- DTXCID5090963
- MFCD00937905
- C27H21ClFN3O2
- Lixivaptan [USAN]
- LIXIVAPTAN [MI]
Look up LIXIVAPTAN in the interactive SynDRA portal →